Document:

Exhibit
10.32

 

NEITHER
THIS SECURITY NOR THE SECURITIES AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE
COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT
OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO,
THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A
LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.
THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

COMMON
STOCK PURCHASE WARRANT 

 

CIPHERLOC
CORPORATION

 

Warrant
Shares: 75,000

Date
of Issuance: December 14, 2017 (“Issuance Date”)

 

This
COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received (in connection with the issuance
of the $300,000.00 convertible debenture to the Holder (as defined below) of even date) (the “Note”), Peak One Opportunity
Fund, LP, a Delaware limited partnership (including any permitted and registered assigns, the “Holder”), is
entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or
after the date of issuance hereof, to purchase from Cipherloc Corporation, a Texas corporation (the “Company”),
up to 75,000 shares of Common Stock (as defined below) (the “Warrant Shares”) (whereby such number may be adjusted
from time to time pursuant to the terms and conditions of this Warrant) at the Exercise Price per share then in effect. This Warrant
is issued by the Company as of the date hereof in connection with that certain securities purchase agreement dated December 14,
by and among the Company and the Holder (the “Purchase Agreement”).

 

Capitalized
terms used in this Warrant shall have the meanings set forth in the Purchase Agreement unless otherwise defined in the body of
this Warrant or in Section 12 below. For purposes of this Warrant, the term “Exercise Price” shall mean $2.00,
subject to adjustment as provided herein (including but not limited to cashless exercise), and the term “Exercise Period”
shall mean the period commencing on the Issuance Date and ending on 5:00 p.m. eastern standard time on the five-year anniversary
thereof.

 

1.
EXERCISE OF WARRANT.

 

(a)
Mechanics of Exercise. Subject to the terms and conditions hereof, the rights represented by this Warrant may be exercised
in whole or in part at any time or times during the Exercise Period by delivery of a written notice, in the form attached hereto
as Exhibit A (the “Exercise Notice”), of the Holder’s election to exercise this Warrant. The Holder
shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Partial exercises of this Warrant
resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering
the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased.
On or before the third Trading Day (the “Warrant Share Delivery Date”) following the date on which the Company
shall have received the Exercise Notice, and upon receipt by the Company of payment to the Company of an amount equal to the applicable
Exercise Price multiplied by the number of Warrant Shares as to which all or a portion of this Warrant is being exercised (the
“Aggregate Exercise Price” and together with the Exercise Notice, the “Exercise Delivery Documents”)
in cash or by wire transfer of immediately available funds (or by cashless exercise, in which case there shall be no Aggregate
Exercise Price provided), the Company shall (or direct its transfer agent to) issue and dispatch by overnight courier to the address
as specified in the Exercise Notice, a certificate, registered in the Company’s share register in the name of the Holder
or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. Upon delivery
of the Exercise Delivery Documents, the Holder shall be deemed for all corporate purposes to have become the holder of record
of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the certificates
evidencing such Warrant Shares. If this Warrant is submitted in connection with any exercise and the number of Warrant Shares
represented by this Warrant submitted for exercise is greater than the number of Warrant Shares being acquired upon an exercise,
then the Company shall as soon as practicable and in no event later than three Business Days after any exercise and at its own
expense, issue a new Warrant (in accordance with Section 6) representing the right to purchase the number of Warrant Shares purchasable
immediately prior to such exercise under this Warrant, less the number of Warrant Shares with respect to which this Warrant is
exercised.

 

    	 

    	 

    

 

If
the Company fails to cause its transfer agent to transmit to the Holder the respective shares of Common Stock by the respective
Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise in Holder’s sole discretion, and
such failure shall be deemed an event of default under the Note.

 

If
the Market Price of one share of Common Stock is greater than the Exercise Price, the Holder may elect to receive Warrant Shares
pursuant to a cashless exercise, in lieu of a cash exercise, equal to the value of this Warrant determined in the manner described
below (or of any portion thereof remaining unexercised) by surrender of this Warrant and a Notice of Exercise, in which event
the Company shall issue to Holder a number of Common Stock computed using the following formula:

 

X
= Y (A-B)

   A

 

	 	Where
    	X
    =	the
    number of Shares to be issued to Holder.
	 	 	 	 
	 	 	Y
    =	the
    number of Warrant Shares that the Holder elects to purchase under this Warrant (at the date of such calculation).
	 	 	 	 
	 	 	A
    =	the
    Market Price (at the date of such calculation).
	 	 	 	 
	 	 	B
    =	Exercise
    Price (as adjusted to the date of such calculation).

 

(b)
No Fractional Shares. No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment
pursuant hereto. All Warrant Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes
of determining whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise
would result in the issuance of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder
otherwise entitled to such fraction a sum in cash equal to the product resulting from multiplying the then-current fair market
value of a Warrant Share by such fraction.

 

(c)
Holder’s Exercise Limitations. The Company shall not effect any exercise of this Warrant, and a Holder shall not
have the right to exercise any portion of this Warrant, to the extent that after giving effect to issuance of Warrant Shares upon
exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder’s Affiliates, and any other
persons acting as a group together with the Holder or any of the Holder’s Affiliates), would beneficially own in excess
of the Beneficial Ownership Limitation, as defined below. For purposes of the foregoing sentence, the number of shares of Common
Stock beneficially owned by the Holder and its Affiliates shall include the number of shares of Common Stock issuable upon exercise
of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock
which would be issuable upon (i) exercise of the remaining, non-exercised portion of this Warrant beneficially owned by the Holder
or any of its Affiliates and (ii) exercise or conversion of the unexercised or non-converted portion of any other securities of
the Company (including without limitation any other Common Stock Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates. Except as set forth in
the preceding sentence, for purposes of this paragraph (d), beneficial ownership shall be calculated in accordance with Section
13(d) of the Exchange Act, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation
is in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be
filed in accordance therewith. To the extent that the limitation contained in this paragraph applies, the determination of whether
this Warrant is exercisable (in relation to other securities owned by the Holder together with any affiliates) and of which portion
of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall
be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned
by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial
Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.

 

    	2

    	 

    

 

For
purposes of this paragraph, in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of
outstanding shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the
Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the
Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the request of a Holder, the
Company shall within two Trading Days confirm to the Holder the number of shares of Common Stock then outstanding. In any case,
the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities
of the Company, including this Warrant, by the Holder or its affiliates since the date as of which such number of outstanding
shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of
shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon
exercise of this Warrant. Upon no fewer than 61 days’ prior notice to the Company, a Holder may increase or decrease the
Beneficial Ownership Limitation provisions of this paragraph, provided that the Beneficial Ownership Limitation in no event exceeds
9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common
Stock upon exercise of this Warrant held by the Holder and the provisions of this paragraph shall continue to apply. Any such
increase or decrease will not be effective until the 61st day after such notice is delivered to the Company and shall only apply
to such Holder and no other Holder. The limitations contained in this paragraph shall apply to a successor Holder of this Warrant.

 

2.
ADJUSTMENTS. The Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows:

 

(a)
Distribution of Assets. If the Company shall declare or make any dividend or other distribution of its assets (or rights
to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including without limitation
any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate
rearrangement or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant,
then, in each such case:

 

(i)
any Exercise Price in effect immediately prior to the close of business on the record date fixed for the determination of holders
of shares of Common Stock entitled to receive the Distribution shall be reduced, effective as of the close of business on such
record date, to a price determined by multiplying such Exercise Price by a fraction (i) the numerator of which shall be the Closing
Sale Price of the shares of Common Stock on the Trading Day immediately preceding such record date minus the value of the Distribution
(as determined in good faith by the Company’s Board of Directors) applicable to one share of Common Stock, and (ii) the
denominator of which shall be the Closing Sale Price of the shares of Common Stock on the Trading Day immediately preceding such
record date; and

 

(ii)
the number of Warrant Shares shall be increased to a number of shares equal to the number of shares of Common Stock obtainable
immediately prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock
entitled to receive the Distribution multiplied by the reciprocal of the fraction set forth in the immediately preceding clause
(i); provided, however, that in the event that the Distribution is of shares of common stock of a company (other than the Company)
whose common stock is traded on a national securities exchange or a national automated quotation system (“Other Shares
of Common Stock”), then the Holder may elect to receive a warrant to purchase Other Shares of Common Stock in lieu of
an increase in the number of Warrant Shares, the terms of which shall be identical to those of this Warrant, except that such
warrant shall be exercisable into the number of shares of Other Shares of Common Stock that would have been payable to the Holder
pursuant to the Distribution had the Holder exercised this Warrant immediately prior to such record date and with an aggregate
exercise price equal to the product of the amount by which the exercise price of this Warrant was decreased with respect to the
Distribution pursuant to the terms of the immediately preceding clause (i) and the number of Warrant Shares calculated in accordance
with the first part of this clause (ii).

 

    	3

    	 

    

 

(b)
Anti-Dilution Adjustments to Exercise Price. If the Company or any Subsidiary thereof, as applicable, at any time while
this Warrant is outstanding, shall sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose
of or issue (or announce any offer, sale, grant or any option to purchase or other disposition) any Common Stock or securities
entitling any person or entity to acquire shares of Common Stock (upon conversion, exercise or otherwise) (including but not limited
to under the Debenture), at an effective price per share less than the then Exercise Price (such lower price, the “Base
Share Price” and such issuances collectively, a “Dilutive Issuance”) (if the holder of the Common
Stock or Common Stock Equivalents so issued shall at any time, whether by operation of purchase price adjustments, reset provisions,
floating conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued
in connection with such issuance, be entitled to receive shares of Common Stock at an effective price per share which is less
than the Exercise Price, such issuance shall be deemed to have occurred for less than the Exercise Price on such date of the Dilutive
Issuance), then the Exercise Price shall be reduced at the option of the Holder and only reduced to equal the Base Share Price,
and the number of Warrant Shares issuable hereunder shall be increased such that the aggregate Exercise Price payable hereunder,
after taking into account the decrease in the Exercise Price, shall be equal to the aggregate Exercise Price prior to such adjustment.
Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued. The Company shall notify the
Holder in writing, no later than the Trading Day following the issuance of any Common Stock or Common Stock Equivalents subject
to this Section 2(b), indicating therein the applicable issuance price, or applicable reset price, exchange price, conversion
price and other pricing terms (such notice the “Dilutive Issuance Notice”). For purposes of clarification,
whether or not the Company provides a Dilutive Issuance Notice pursuant to this Section 2(b), upon the occurrence of any Dilutive
Issuance, after the date of such Dilutive Issuance the Holder is entitled to receive a number of Warrant Shares based upon the
Base Share Price regardless of whether the Holder accurately refers to the Base Share Price in the Notice of Exercise.

 

3.
FUNDAMENTAL TRANSACTIONS. If, at any time while this Warrant is outstanding, (i) the Company effects any merger of the
Company with or into another entity and the Company is not the surviving entity (such surviving entity, the “Successor
Entity”), (ii) the Company effects any sale of all or substantially all of its assets in one or a series of related
transactions, (iii) any tender offer or exchange offer (whether by the Company or by another individual or entity, and approved
by the Company) is completed pursuant to which holders of Common Stock are permitted to tender or exchange their shares of Common
Stock for other securities, cash or property and the holders of at least 50% of the Common Stock accept such offer, or (iv) the
Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is
effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision or combination
of shares of Common Stock) (in any such case, a “Fundamental Transaction”), then, upon any subsequent exercise
of this Warrant, the Holder shall have the right to receive the number of shares of Common Stock of the Successor Entity or of
the Company and any additional consideration (the “Alternate Consideration”) receivable upon or as a result
of such reorganization, reclassification, merger, consolidation or disposition of assets by a holder of the number of shares of
Common Stock for which this Warrant is exercisable immediately prior to such event (disregarding any limitation on exercise contained
herein solely for the purpose of such determination). For purposes of any such exercise, the determination of the Exercise Price
shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable
in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among
the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate
Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental
Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of
this Warrant following such Fundamental Transaction. To the extent necessary to effectuate the foregoing provisions, any Successor
Entity in such Fundamental Transaction shall issue to the Holder a new warrant consistent with the foregoing provisions and evidencing
the Holder’s right to exercise such warrant into Alternate Consideration.

 

4.
NON-CIRCUMVENTION. The Company covenants and agrees that it will not, by amendment of its certificate of incorporation,
bylaws or through any reorganization, transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or
sale of securities, or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of
this Warrant, and will at all times in good faith carry out all the provisions of this Warrant and take all action as may be required
to protect the rights of the Holder. Without limiting the generality of the foregoing, the Company (i) shall not increase the
par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect,
(ii) shall take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully
paid and non-assessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, for so long as this Warrant
is outstanding, have authorized and reserved, free from preemptive rights, ten (10) times the number of shares of Common Stock
into which the Warrants are then exercisable into to provide for the exercise of the rights represented by this Warrant (without
regard to any limitations on exercise).

 

    	4

    	 

    

 

5.
WARRANT HOLDER NOT DEEMED A STOCKHOLDER. Except as otherwise specifically provided herein, this Warrant, in and of itself,
shall not entitle the Holder to any voting rights or other rights as a stockholder of the Company. In addition, nothing contained
in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this
Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors
of the Company.

 

6.
REISSUANCE.

 

(a)
Lost, Stolen or Mutilated Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company will, on such terms
as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender
thereof), issue a new Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed.

 

(b)
Issuance of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant,
such new Warrant shall be of like tenor with this Warrant, and shall have an issuance date, as indicated on the face of such new
Warrant which is the same as the Issuance Date.

 

7.
TRANSFER.

 

(a)
Notice of Transfer. The Holder agrees to give written notice to the Company before transferring this Warrant or transferring
any Warrant Shares of such Holder’s intention to do so, describing briefly the manner of any proposed transfer. Promptly
upon receiving such written notice, the Company shall present copies thereof to the Company’s counsel. If the proposed transfer
may be effected without registration or qualification (under any federal or state securities laws), the Company, as promptly as
practicable, shall notify the Holder thereof, whereupon the Holder shall be entitled to transfer this Warrant or to dispose of
Warrant Shares received upon the previous exercise of this Warrant, all in accordance with the terms of the notice delivered by
the Holder to the Company; provided, however, that an appropriate legend may be endorsed on this Warrant or the certificates for
such Warrant Shares respecting restrictions upon transfer thereof necessary or advisable in the opinion of counsel and satisfactory
to the Company to prevent further transfers which would be in violation of Section 5 of the Securities Act and applicable state
securities laws; and provided further that the prospective transferee or purchaser shall execute the Assignment of Warrant attached
hereto as Exhibit B and such other documents and make such representations, warranties, and agreements as may be required
solely to comply with the exemptions relied upon by the Company for the transfer or disposition of the Warrant or Warrant Shares.

 

(b)
If the proposed transfer or disposition of this Warrant or such Warrant Shares described in the written notice given pursuant
to this Section 7 may not be effected without registration or qualification of this Warrant or such Warrant Shares, the Holder
will limit its activities in respect to such transfer or disposition as are permitted by law.

 

(c)
Any transferee of all or a portion of this Warrant shall succeed to the rights and benefits of the initial Holder of this Warrant.

 

8.
NOTICES. Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall
be given in accordance with the notice provisions contained in the Purchase Agreement. The Company shall provide the Holder with
prompt written notice (i) immediately upon any adjustment of the Exercise Price, setting forth in reasonable detail, the calculation
of such adjustment and (ii) at least 20 days prior to the date on which the Company closes its books or takes a record (A) with
respect to any dividend or distribution upon the shares of Common Stock, (B) with respect to any grants, issuances or sales of
any stock or other securities directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock
or other property, pro rata to the holders of shares of Common Stock or (C) for determining rights to vote with respect to any
Fundamental Transaction, dissolution or liquidation, provided in each case that such information shall be made known to the public
prior to or in conjunction with such notice being provided to the Holder.

 

9.
AMENDMENT AND WAIVER. The terms of this Warrant may be amended or waived (either generally or in a particular instance
and either retroactively or prospectively) only with the written consent of the Company and the Holder.

 

    	5

    	 

    

 

10.
GOVERNING LAW. This Warrant shall be governed by and construed in accordance with the laws of the State of Nevada without
regard to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated
by this Warrant shall be brought only in the state courts or federal courts located in the State of Florida, County of Miami-Dade.
The parties to this Warrant hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder
and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non conveniens. EACH PARTY
HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE
HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT ENTERED INTO IN CONNECTION WITH OR ARISING OUT OF THIS AGREEMENT, ANY OTHER
TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY. The prevailing party shall be entitled to recover
from the other party its reasonable attorney’s fees and costs. In the event that any provision of this Warrant or any other
agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law, then such
provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform with
such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the validity
or enforceability of any other provision of any agreement. Each party hereby irrevocably waives personal service of process and
consents to process being served in any suit, action or proceeding in connection with this Agreement or any other Transaction
Document by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient
service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process
in any other manner permitted by law.

 

11.
ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and
conditions contained herein.

 

12.
CERTAIN DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:

 

(a)
“Nasdaq” means www.Nasdaq.com.

 

(b)
“Closing Sale Price” means, for any security as of any date, (i) the last closing trade price for such security
on the Principal Market, as reported by Nasdaq, or, if the Principal Market begins to operate on an extended hours basis and does
not designate the closing trade price, then the last trade price of such security prior to 4:00 p.m., New York time, as reported
by Nasdaq, or (ii) if the foregoing does not apply, the last trade price of such security in the over-the-counter market for such
security as reported by Nasdaq, or (iii) if no last trade price is reported for such security by Nasdaq, the average of the bid
and ask prices of any market makers for such security as reported by the OTC Markets. If the Closing Sale Price cannot be calculated
for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall
be the fair market value as mutually determined by the Company and the Holder. All such determinations to be appropriately adjusted
for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

 

(c)
“Common Stock” means the Company’s common stock, and any other class of securities into which such securities
may hereafter be reclassified or changed.

 

(d)
“Common Stock Equivalents” means any securities of the Company that would entitle the holder thereof to acquire
at any time Common Stock, including without limitation any debt, preferred stock, rights, options, warrants or other instrument
that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock.

 

(e)
“Dilutive Issuance” is any issuance of Common Stock or Common Stock Equivalents described in Section 2(b) above;
provided, however, that a Dilutive Issuance shall not include any Exempt Issuance.

 

(f)
“Exempt Issuance” means the issuance of (i) shares of Common Stock or options to officers or directors of the
Company pursuant to any stock or option plan duly adopted by a majority of the non-employee members of the Board of Directors
of the Company or a majority of the members of a committee of non-employee directors established for such purpose, (ii) securities
issued pursuant to acquisitions approved by a majority of the disinterested directors of the Company, and (iii) shares of Common
Stock issued pursuant to any real property leasing arrangement or debt financing from a bank approved by the Board of Directors
of the Company.

 

    	6

    	 

    

 

(g)
“Principal Market” means the primary national securities exchange on which the Common Stock is then traded.

 

(h)
“Market Price” means the highest traded price of the Common Stock during the thirty (30) Trading Days prior
to the date of the respective Exercise Notice.

 

(i)
“Trading Day” means (i) any day on which the Common Stock is listed or quoted and traded on its Principal Market,
(ii) if the Common Stock is not then listed or quoted and traded on any national securities exchange, then a day on which trading
occurs on any over-the-counter markets, or (iii) if trading does not occur on the over-the-counter markets, any Business Day.

 

*
* * * * * *

 

    	7

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be duly executed as of the Issuance Date set forth above.

 

 

	 	CIPHERLOC
    CORPORATION
	 	 	 
	 	By:	/s/
    Michael De La Garza
	 	Name:	Michael
    De La Garza
	 	Title:	Chief
    Executive Officer

 

    	 

    	 

    

 

EXHIBIT
A

 

EXERCISE
NOTICE

 

(To
be executed by the registered holder to exercise this Common Stock Purchase Warrant)

 

The
Undersigned holder hereby exercises the right
to purchase _________________ of the shares of Common Stock (“Warrant Shares”) of Cipherloc Corporation, a Texas corporation
(the “Company”), evidenced by the attached copy of the Common Stock Purchase Warrant (the “Warrant”).
Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.

 

	1.	Form
    of Exercise Price. The Holder intends that payment of the Exercise Price shall be made as (check one):
	 	 	 	 
	 	 	[  ]	a
    cash exercise with respect to _________________ Warrant Shares; or
	 	 	[  ]	by
cashless exercise pursuant to the Warrant.
	 	 	 	 
	2.	Payment
    of Exercise Price. If cash exercise is selected above, the holder shall pay the applicable Aggregate Exercise Price in
    the sum of $___________________ to the Company in accordance with the terms of the Warrant.
	 	 
	3.	Delivery
    of Warrant Shares. The Company shall deliver to the holder __________________ Warrant Shares in accordance with the terms
    of the Warrant. 

 

Date:
________________________

 

	 	(Print
    Name of Registered Holder) 
	 	 	       
	 	By:
    	 
	 	Name:
    	 
	 	Title:
    	 

 

    	 

    	 

    

 

EXHIBIT
B

 

ASSIGNMENT
OF WARRANT

 

(To
be signed only upon authorized transfer of the Warrant)

 

For
Value Received, the undersigned hereby sells,
assigns, and transfers unto ____________________ the right to purchase _______________ shares of common stock of Cipherloc Corporation,
to which the within Common Stock Purchase Warrant relates and appoints ____________________, as attorney-in-fact, to transfer
said right on the books of Cipherloc Corporation with full power of substitution and re-substitution in the premises. By accepting
such transfer, the transferee has agreed to be bound in all respects by the terms and conditions of the within Warrant.

 

Dated:
__________________

 

	 	 
	 	(Signature)
    *
	 	 
	 	 
	 	(Name)
    
	 	 
	 	 
	 	(Address)
	 	 
	 	 
	 	(Social
    Security or Tax Identification No.) 

 

*
The signature on this Assignment of Warrant must correspond to the name as written upon the face of the Common Stock Purchase
Warrant in every particular without alteration or enlargement or any change whatsoever. When signing on behalf of a corporation,
partnership, trust or other entity, please indicate your position(s) and title(s) with such entity.Exhibit
10.33

 

SECURITIES
PURCHASE AGREEMENT

 

THIS
SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 14, 2017, is entered into by and between
CIPHERLOC CORPORATION, a Texas corporation, (the “Company”) and Peak One Opportunity
Fund, L.P., a Delaware limited partnership (the “Buyer”).

 

WITNESSETH:

 

WHEREAS,
the Company and the Buyer are executing and delivering this Agreement in accordance with and in reliance upon the exemption from
securities registration afforded, inter alia, by Rule 506 under Regulation D (“Regulation D”) as promulgated
by the United States Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the
“1933 Act”), and/or Section 4(2) of the 1933 Act; and

 

WHEREAS,
the Buyer wishes to purchase from the Company, and the Company wishes to sell the Buyer, upon the terms and subject to the
conditions of this Agreement, securities consisting of the Company’s Convertible Debentures due three years from the respective
dates of issuance (the “Debentures”), each of which are in the form of Exhibit A hereto, which will be convertible
into shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), in the aggregate
principal amount of up to Six Hundred Thousand and 00/100 Dollars ($600,000.00), for an aggregate Purchase Price of up to Five
Hundred Forty Thousand and 00/100 Dollars ($540,000.00), as well as that certain common stock purchase warrant for the purchase
of up to 75,000 shares of Common Stock (the “Warrant”), all upon the terms and subject to the conditions of this Agreement,
the Debentures, and other related documents;

 

NOW
THEREFORE, in consideration of the premises and the mutual covenants contained herein and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

 

1.
DEFINITIONS; AGREEMENT TO PURCHASE.

 

a.
Certain Definitions. As used herein, each of the following terms has the meaning set forth below, unless the context otherwise
requires:

 

(i)
“Affiliate” means, with respect to a specific Person referred to in the relevant provision, another Person who or
which controls or is controlled by or is under common control with such specified Person.

 

(ii)
“Certificates” means certificates representing the Conversion Shares issuable hereunder, each duly executed on behalf
of the Company and issued hereunder.

 

(iii)
“Closing Date” means the date on which one of the two (2) Closings are held, which are the Signing Closing Date and
the Second Closing Date.

 

(iv)
[Reserved]

 

(v)
“Commitment Fee” shall have the meaning ascribed to such term in Section 12(a).

 

(vi)
“Common Stock” shall have the meaning ascribed to such term in the Recitals.

 

(vii)
“Conversion Amount” shall mean the Conversion Amount as defined in the Debentures, provided, however that for
purposes of the foregoing calculation, the full indebtedness under the Debentures shall be deemed immediately convertible, notwithstanding
the 4.99% limitation on ownership set forth in the Debentures.

 

(viii)
“Conversion Price” means the Conversion Price as defined in the Debentures.

 

    	 

    	 

    

 

(ix)
“Conversion Shares” means the shares of Common Stock issuable upon conversion of the Debentures.

 

(x)
“DWAC Operational” means that the Common Stock is eligible for clearing through the Depository Trust Company (“DTC”)
via the DTC’s Deposit Withdrawal Agent Commission or “DWAC” system and active and in good standing for DWAC
issuance by the Transfer Agent (as defined herein).

 

(xi)
“Dollars” or “$” means United States Dollars.

 

(xii)
“Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

(xiii)
“Investments” means Peak One Investments, LLC, the general partner of the Buyer.

 

(xiv)
“Irrevocable Resolutions” has the meaning set forth in Section 8(i).

 

(xv)
“Market Price of the Common Stock” means (x) the closing bid price of the Common Stock for the period indicated in
the relevant provision hereof (unless a different relevant period is specified in the relevant provision), as reported by Bloomberg,
LP or, if not so reported, as reported on the OTCQB, OTCQX or OTC Pink or (y) if the Common Stock is listed on a stock exchange,
the closing price on such exchange, as reported by Bloomberg LP.

 

(xvi)
“Material Adverse Effect” means a material adverse effect on the business, operations or condition (financial or otherwise)
or results of operation of the Company and its Subsidiaries taken as a whole, in the reasonable commercial discretion of the Buyer,
irrespective of any finding of fault, magnitude of liability (or lack of financial liability). Without limiting the generality
of the foregoing, the occurrence of any of the following, in the reasonable commercial discretion of the Buyer, shall be considered
a Material Adverse Effect: (i) any final money, judgment, writ or warrant of attachment, or similar process (including an arbitral
determination) in excess of Fifty Thousand Dollars ($50,000) shall be entered or filed against the Company or any of its Subsidiaries
(including, in any event, products liability claims against the Company or its Subsidiaries), (ii) the suspension or withdrawal
of any governmental authority or permit pertaining to a material amount of the Company’s or any Subsidiary’s products
or services, (iii) the loss of any material insurance coverage (including, in any case, comprehensive general liability coverage,
products liability coverage or directors and officers coverage, in each case in effect at the time of execution and delivery of
this Agreement), (iv) an action by a regulatory agency or governmental body affecting the Common Stock (including, without limitation,
(1) the commencement of any regulatory investigation of which the Company is aware, the suspension of trading of the Common Stock
by the Financial Industry Regulation Authority (“FINRA”), the SEC, the OTC Bulletin Board (“OTCBB”) or
the OTC Markets Group, Inc., the failure of the Common Stock to be DTC eligible or the placing of the Common Stock on the DTC
“chill list” or (2) the engaging in any market manipulation or other unlawful or improper trading or other activity
by any Affiliate), (v) the Company’s independent registered accountants shall resign under circumstances where a disagreement
exists between the Company and its independent registered accountants, (vi) the Company shall fail to timely file any disclosure
document as required by applicable federal or state securities laws and regulations or by the rules and regulations of any exchange,
trading market or quotation system to which the Company or the Common Stock is subject, or (vii) the Chief Executive Officer of
the Company or any other key full-time officer or director of the Company, shall, for any reason (including, without limitation,
termination, resignation, retirement, death or disability) cease to act on behalf of the Company in the same role and to the same
extent as his or her involvement as of the date of execution and delivery of this Agreement.

 

(xvii)
“Person” means any living person or any entity, such as, but not necessarily limited to, a corporation, partnership
or trust.

 

(xviii)
“Purchase Price” means the price that the Buyer pays for the Debentures at each respective Closing, which are the
Signing Purchase Price and the Second Purchase Price, as the case may be.

 

    	2

    	 

    

 

(xix)
“Registrable Securities” shall mean the Conversion Shares, and, to the extent applicable, and any other shares of
capital stock or other securities of the Company or any successor to the Company that are issued upon exchange of Conversion Shares
and/or such Restricted Stock.

 

(xx)
“Registration Statement” shall mean a registration statement on Form S-1 (or any successor thereto) filed or contemplated
to be filed by the Company with the SEC under the Securities Act.

 

(xxi)
“Restricted Stock” shall mean shares of Common Stock which are not freely trading shares when issued.

 

(xxii)
“Securities” means the Debentures and the Shares.

 

(xxiii)
“Shares” means the Conversion Shares.

 

(xxiv)
“Second Closing Date” shall have the meaning ascribed to such term in Section 6(b).

 

(xxv)
“Second Debenture” means the second of the three (3) Debentures, in the principal amount of Three Hundred Thousand
and 00/100 Dollars ($300,000.00), which is issued by the Company to the Buyer on the Second Closing Date.

 

(xxvi)
“Second Purchase Price” shall be Two Hundred Seventy Thousand and 00/100 Dollars ($270,000.00)

 

(xxvii)
“Signing Closing Date” shall have the meaning ascribed to such term in Section 6(a).

 

(xxviii)
“Signing Debenture” means the first of the three (3) Debentures, in the principal amount of Three Hundred Thousand
and 00/100 Dollars ($300,000.00), to be issued by the Company to the Buyer on the Signing Closing Date.

 

(xxix)
“Signing Purchase Price” shall be Two Hundred Seventy Thousand and 00/100 Dollars ($270,000.00).

 

(xxx)
“Subsidiary” shall have the meaning ascribed to such term in Section 3(b).

 

(xxxi)
[Intentionally Omitted].

 

(xxxii)
[Intentionally Omitted].

 

(xxxiii)
[Intentionally Omitted].

 

(xxxiv)
“Transaction Documents” means, collectively, this Agreement, the Debentures, the Transfer Agent Instruction Letter,
the Irrevocable Resolutions and the other agreements, documents and instruments contemplated hereby or thereby.

 

(xxxv)
“Transfer Agent” shall have the meaning ascribed to such term in Section 4(a).

 

(xxxvi)
“Transfer Agent Instruction Letter” shall have the meaning ascribed to such term in Section 5(a).

 

    	3

    	 

    

 

b.
Purchase and Sale of Debentures.

 

(i)
The Buyer agrees to purchase from the Company, and the Company agrees to sell to the Buyer, the Debentures and Warrant on the
terms and conditions set forth below in this Agreement and the other Transaction Documents. The Warrant shall be earned in full
as an inducement fee as of the Signing Closing Date.

 

(ii)
Subject to the terms and conditions of this Agreement and the other Transaction Documents, the Buyer will purchase the Debentures
and Warrant at certain closings (each, a “Closing”) to be held on certain respective Closing Dates.

 

c.
[Reserved] 

 

(i)
[Reserved]

 

(ii)
[Reserved]

 

2.
BUYER’S REPRESENTATIONS, WARRANTIES, ETC.

 

The
Buyer represents and warrants to, and covenants and agrees with, the Company as follows:

 

a.
Investment Purpose. Without limiting the Buyer’s right to sell the Shares pursuant to a Registration Statement, Buyer
is purchasing the Debentures, and will be acquiring the Conversion Shares, for its own account for investment only and not with
a view towards the public sale or distribution thereof and not with a view to or for sale in connection with any distribution
thereof.

 

b.
Accredited Investor Status. Buyer is (i) an “accredited investor” as that term is defined in Rule 501 of the
General Rules and Regulations under the 1933 Act by reason of Rule 501(a)(3), (ii) experienced in making investments of the kind
described in this Agreement and the related documents, (iii) able, by reason of the business and financial experience of its officers
(if an entity) and professional advisors (who are not affiliated with or compensated in any way by the Company or any of its affiliates
or selling agents), to protect its own interests in connection with the transactions described in this Agreement, and the related
documents, and (iv) able to afford the entire loss of its investment in the Securities.

 

c.
Subsequent Offers and Sales. All subsequent offers and sales of the Securities by the Buyer shall be made pursuant to registration
of the Shares under the 1933 Act or pursuant to an exemption from registration and compliance with applicable states’ securities
laws.

 

d.
Reliance on Exemptions. Buyer understands that the Securities are being offered and sold to it in reliance on specific
exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying
upon the truth and accuracy of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments
and understandings of the Buyer set forth herein in order to determine the availability of such exemptions and the eligibility
of the Buyer to acquire the Securities.

 

e.
Information. Buyer and its advisors have been furnished with all materials relating to the business, finances and operations
of the Company and materials relating to the offer and sale of the Securities which have been requested by the Buyer. Buyer and
its advisors have been afforded the opportunity to ask questions of the Company and have received complete and satisfactory answers
to any such inquiries. Without limiting the generality of the foregoing, Buyer has also had the opportunity to obtain and to review
the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2016, and Quarterly Report on Form 10-Q
for the fiscal quarter ended June 30, 2017 (collectively, the “SEC Documents”).

 

f.
Investment Risk. Buyer understands that its investment in the securities constitutes high risk investment, its investment
in the Securities involves a high degree of risk, including the risk of loss of the Buyer’s entire investment.

 

    	4

    	 

    

 

g.
Governmental Review. Buyer understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities.

 

h.
Organization; Authorization. Buyer is duly organized, validly existing and in good standing under the laws of the jurisdiction
of its organization. This Agreement and the other Transaction Documents have been duly and validly authorized, executed and delivered
on behalf of the Buyer and create a valid and binding agreement of the Buyer enforceable in accordance with its terms, subject
as to enforceability to general principles of equity and to bankruptcy, insolvency, moratorium and other similar laws affecting
the enforcement of creditors’ rights generally.

 

i.
Residency. The state in which any offer to sell Securities hereunder was made to or accepted by the Buyer is the state
shown as the Buyer’s address contained herein, and Buyer is a resident of such state only.

 

3.
COMPANY REPRESENTATIONS AND WARRANTIES, ETC. 

 

The
Company represents and warrants to the Buyer that:

 

a.
Concerning the Debentures and the Shares. There are no preemptive rights of any stockholder of the Company to acquire the
Debentures or the Shares.

 

b.
Organization; Subsidiaries; Reporting Company Status. Attached hereto as Schedule 3(b) is an organizational chart
describing all of the Company’s wholly-owned and majority-owned subsidiaries (the “Subsidiaries”) and other
Affiliates, including the relationships among the Company and such Subsidiaries, including as to each Subsidiary its jurisdiction
of organization and the percentage of ownership held by the Company, and the parent company of the Subsidiary, including the percentage
of ownership of the Company held by it. The Company and each Subsidiary is a corporation or other form of businesses entity duly
organized, validly existing and in good standing under the laws its respective jurisdiction of organization, and each of them
has the requisite corporate or other power to own its properties and to carry on its business as now being conducted. The Company
and each Subsidiary is duly qualified as a foreign corporation or other entity to do business and is in good standing in each
jurisdiction where the nature of the business conducted or property owned by it makes such qualification necessary, other than
those jurisdictions in which the failure to so qualify would not have a Material Adverse Effect. The Common Stock is listed and
traded on the OTCM (as defined below) (trading symbol: CLOK). The Company has received no notice, either oral or written, from
FINRA, the SEC, or any other organization, with respect to the continued eligibility of the Common Stock for such listing, and
the Company has maintained all requirements for the continuation of such listing. The Company is an operating company in that,
among other things (A) it primarily engages, wholly or substantially, directly or indirectly through a majority owned Subsidiary
or Subsidiaries, in the production or sale, or the research or development, of a product or service other than the investment
of capital, (B) it is not an individual or sole proprietorship, (C) it is not an entity with no specific business plan or purpose
and its business plan is not to engage in a merger or acquisition with an unidentified company or companies or other entity or
person, and (D) it intends to use the proceeds from the sale of the Debentures solely for the operation of the Company’s
business and uses other than personal, family, or household purposes.

 

c.
Authorized Shares. Schedule 3(c) sets forth all capital stock and derivative securities of the Company that
are authorized for issuance and that are issued and outstanding. All issued and outstanding shares of Common Stock have been duly
authorized and validly issued and are fully paid and nonassessable. The Company has sufficient authorized and unissued shares
of Common Stock as may be necessary to effect the issuance of the Shares, assuming the prior issuance and exercise, exchange or
conversion, as the case may be, of all derivative securities authorized, as indicated in Schedule 3(c). The Shares have
been duly authorized and, when issued upon conversion of, or as interest on, the Debentures, the Shares will be duly and validly
issued, fully paid and non-assessable and will not subject the holder thereof to personal liability by reason of being such holder.
At all times, the Company shall keep available and reserved for issuance to the holders of the Debentures shares of Common Stock
duly authorized for issuance against the Debentures.

 

    	5

    	 

    

 

d.
Authorization. This Agreement, the issuance of the Debentures (including without limitation the incurrence of indebtedness
thereunder), the issuance of the Conversion Shares under the Debentures, and the other transactions contemplated by the Transaction
Documents, have been duly, validly and irrevocably authorized by the Company, and this Agreement has been duly executed and delivered
by the Company. The Company’s board of directors, in the exercise of its fiduciary duties, has irrevocably approved the
entry into and performance of the Transaction Documents, including, without limitation the sale of the Debentures and the issuance
of Conversion Shares, based upon a reasonable inquiry concerning the Company’s financing objectives and financial situation.
Each of the Transaction Documents, when executed and delivered by the Company, are and will be, valid, legal and binding agreements
of the Company, enforceable in accordance with their respective terms, subject as to enforceability to general principles of equity
and to bankruptcy, insolvency, moratorium, and other similar laws affecting the enforcement of creditors’ rights generally.

 

e.
Non-contravention. The execution and delivery of the Transaction Documents, the issuance of the Securities and the consummation
by the Company of the other transactions contemplated by this Agreement and the Debentures (including without limitation the incurrence
of indebtedness thereunder) do not and will not conflict with or result in a breach by the Company of any of the terms or provisions
of, or constitute a default under (i) the articles of incorporation or by-laws of the Company, each as currently in effect, (ii)
any indenture, mortgage, deed of trust, or other material agreement or instrument to which the Company is a party or by which
it or any of its properties or assets are bound, including any listing agreement for the Common Stock, except as herein set forth
or an event which results in the creation of any lien, charge or encumbrance upon any assets of the Company or the triggering
of any anti-dilution rights, rights of first refusal or first offer on the part of holders of the Company’s securities,
(iii) to its knowledge, any existing applicable law, rule, or regulation or any applicable decree, judgment, or order of any court,
United States federal or state regulatory body, administrative agency, or other governmental body having jurisdiction over the
Company or any of its properties or assets, or (iv) the Company’s listing agreement for its Common Stock (if applicable).

 

f.
Approvals. No authorization, approval or consent of any court, governmental body, regulatory agency, self-regulatory organization,
or stock exchange or market or the stockholders of the Company is required to be obtained by the Company for the entering into
and performing this Agreement and the other Transaction Documents (including without limitation the issuance and sale of the Securities
to the Buyer as contemplated by this Agreement) except such authorizations, approvals and consents that have been obtained, or
such authorizations, approvals and consents, the failure of which to obtain would not have a Material Adverse Effect.

 

g.
SEC Filings; Rule 144 Status. None of the SEC Documents contained, at the time they were filed, any untrue statement of
a material fact or omitted to state any material fact required to be stated therein or necessary to make the statements made therein
in light of the circumstances under which they were made, not misleading. The Company timely filed all requisite forms, reports
and exhibits thereto with the SEC as required. The Company is not aware of any event occurring on or prior to the execution and
delivery of this Agreement that would require the filing of, or with respect to which the Company intends to file, a Form 8-K
after such time. The Company satisfies the requirements of Rule 144(i)(2), and the Company shall continue to satisfy all applicable
requirements of Rule 144 (or any successor thereto) for so long as any Securities are outstanding and not registered pursuant
to an effective registration statement filed with the SEC.

 

h.
Absence of Certain Changes. Since June 30, 2017, when viewed from the perspective of the Company and its Subsidiaries taken
as a whole, there has been no material adverse change and no material adverse development in the business, properties, operations,
condition (financial or otherwise), or results of operations of the Company and its Subsidiaries (including, without limitation,
a change or development which constitutes, or with the passage of time is reasonably likely to become, a Material Adverse Effect),
except as disclosed in the SEC Documents. Since June 30, 2017, except as provided in the SEC Documents, the Company has not (i)
incurred or become subject to any material liabilities (absolute or contingent) except liabilities incurred in the ordinary course
of business consistent with past practices; (ii) discharged or satisfied any material lien or encumbrance or paid any material
obligation or liability (absolute or contingent), other than current liabilities paid in the ordinary course of business consistent
with past practices; (iii) declared or made any payment or distribution of cash or other property to stockholders with respect
to its capital stock, or purchased or redeemed, or made any agreements to purchase or redeem, any shares of its capital stock;
(iv) sold, assigned or transferred any other tangible assets, or canceled any debts or claims, except in the ordinary course of
business consistent with past practices; (v) suffered any substantial losses or waived any rights of material value, whether or
not in the ordinary course of business, or suffered the loss of any material amount of existing business; (vi) made any changes
in employee compensation, except in the ordinary course of business consistent with past practices; or (vii) experienced any material
problems with labor or management in connection with the terms and conditions of their employment.

 

    	6

    	 

    

 

i.
Full Disclosure. There is no fact known to the Company (other than general economic conditions known to the public generally
or as disclosed in the SEC Documents) that has not been disclosed in writing to the Buyer that (i) would reasonably be expected
to have a Material Adverse Effect, (ii) would reasonably be expected to materially and adversely affect the ability of the Company
to perform its obligations pursuant to the Transaction Documents, or (iii) would reasonably be expected to materially and adversely
affect the value of the rights granted to the Buyer in the Transaction Documents.

 

j.
Absence of Litigation. Except as described in the SEC Documents, there is no action, suit, proceeding, inquiry or investigation
before or by any court, public board or body pending or, to the knowledge of the Company, threatened against or affecting the
Company, wherein an unfavorable decision, ruling or finding would have a Material Adverse Effect or which would adversely affect
the validity or enforceability of, or the authority or ability of the Company to perform its obligations under, any of the Transaction
Documents. The Company is not a party to or subject to the provisions of, any order, writ, injunction, judgment or decree of any
court or government agency or instrumentality which could reasonably be expected to have a Material Adverse Effect.

 

k.
Absence of Liens. The Company’s assets are not encumbered by any liens or mortgages except as described in the SEC
Documents.

 

l.
Absence of Events of Default. No event of default (or its equivalent term), as defined in the respective agreement, indenture,
mortgage, deed of trust or other instrument, to which the Company is a party, and no event which, with the giving of notice or
the passage of time or both, would become an event of default (or its equivalent term) (as so defined in such document), has occurred
and is continuing, which would have a Material Adverse Effect.

 

m.
No Undisclosed Liabilities or Events. The Company has no liabilities or obligations other than those disclosed in the SEC
Documents or those incurred in the ordinary course of the Company’s business since June 30, 2017, and which individually
or in the aggregate, do not or would not have a Material Adverse Effect. No event or circumstances has occurred or exists with
respect to the Company or its properties, business, condition (financial or otherwise), or results of operations, which, under
applicable law, rule or regulation, requires public disclosure or announcement prior to the date hereof by the Company but which
has not been so publicly announced or disclosed. There are no proposals currently under consideration or currently anticipated
to be under consideration by the Board of Directors or the executive officers of the Company which proposal would (x) change the
articles of incorporation, by-laws or any other charter document of the Company, each as currently in effect, with or without
shareholder approval, which change would reduce or otherwise adversely affect the rights and powers of the shareholders of the
Common Stock or (y) materially or substantially change the business, assets or capital of the Company.

 

n.
No Integrated Offering. Neither the Company nor any of its affiliates nor any Person acting on its or their behalf has,
directly or indirectly, at any time during the six month period immediately prior to the date of this Agreement made any offer
or sales of any security or solicited any offers to buy any security under circumstances that would eliminate the availability
of the exemption from registration under Rule 506 of Regulation D in connection with the offer and sale of the Securities as contemplated
hereby.

 

o.
Dilution. The number of Shares issuable upon conversion of the Debentures may increase substantially in certain circumstances,
including, but not necessarily limited to, the circumstance wherein the Market Price of the Common Stock declines prior to the
conversion of the Debentures. The Company’s executive officers and directors have studied and fully understand the nature
of the securities being sold hereby and recognize that they have a potential dilutive effect and further that the conversion of
the Debentures and/or sale of the Conversion Shares may have an adverse effect on the Market Price of the Common Stock. The Board
of Directors of the Company has concluded, in its good faith business judgment that such issuance is in the best interests of
the Company. The Company specifically acknowledges that its obligation to issue the Conversion Shares upon conversion of the Debentures
is binding upon the Company and enforceable regardless of the dilution such issuance may have on the ownership %s of other shareholders
of the Company.

 

    	7

    	 

    

 

p.
Regulatory Permits. The Company has all such permits, easements, consents, licenses, franchises and other governmental
and regulatory authorizations from all appropriate federal, state, local or other public authorities (“Permits”) as
are necessary to own and lease its properties and conduct its businesses in all material respects in the manner described in the
SEC Documents and as currently being conducted. All such Permits are in full force and effect and the Company has fulfilled and
performed all of its material obligations with respect to such Permits, and no event has occurred that allows, or after notice
or lapse of time would allow, revocation or termination thereof or will result in any other material impairment of the rights
of the holder of any such Permit, subject in each case to such qualification as may be disclosed in the SEC Documents. Such Permits
contain no restrictions that would materially impair the ability of the Company to conduct businesses in the manner consistent
with its past practices. The Company has not received notice or otherwise has knowledge of any proceeding or action relating to
the revocation or modification of any such Permit.

 

q.
Residency. The state in which any offer to sell Securities hereunder was made or accepted by the Seller is the state shown
as the Seller’s address contained herein, and Seller is a resident of such state only.

 

r.
Hazardous Materials. The Company is in compliance with all applicable Environmental Laws in all respects except where the
failure to comply does not have and could not reasonably be expected to have a Material Adverse Effect. For purposes of the foregoing:

 

“Environmental
Laws” means, collectively, the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended,
the Superfund Amendments and Reauthorization Act of 1986, the Resource Conservation and Recovery Act, the Toxic Substances Control
Act, as amended, the Clean Air Act, as amended, the Clean Water Act, as amended, any other “Superfund” or “Superlien”
law or any other applicable federal, state or local statute, law, ordinance, code, rule, regulation, order or decree regulating,
relating to, or imposing liability or standards of conduct concerning, the environment or any Hazardous Material.

 

“Hazardous
Material” means and includes any hazardous, toxic or dangerous waste, substance or material, the generation, handling,
storage, disposal, treatment or emission of which is subject to any Environmental Law.

 

s.
Independent Public Accountants. The Company’s auditor, DBB McKennon, is an independent registered public accounting
firm with respect to the Company, as required by the 1933 Act, the Exchange Act and the rules and regulations promulgated thereunder.

 

t.
Internal Accounting Controls. The Company maintains a system of internal accounting controls sufficient to provide reasonable
assurances that (1) transactions are executed in accordance with management’s general or specific authorization; (2) transactions
are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles
and to maintain accountability for assets; (3) access to assets is permitted only in accordance with management’s general
or specific authorization; and (4) the recorded accountability for assets is compared with existing assets at reasonable intervals
and appropriate action is taken with respect to any differences.

 

u.
Brokers. No Person (other than the Buyer and its principals, employees and agents) is entitled to receive any consideration
from the Company or the Buyer arising from any finder’s agreement, brokerage agreement or other agreement to which the Company
is a party.

 

v.
DWAC Operational; DRS. The Company is currently and shall remain DWAC Operational and eligible for DRS

 

    	8

    	 

    

 

4.
CERTAIN COVENANTS AND ACKNOWLEDGMENTS.

 

a.
Transfer Restrictions. The parties acknowledge and agree that (1) the Debentures have not been registered under the provisions
of the 1933 Act and the Shares have not been registered under the 1933 Act, and may not be transferred unless (A) subsequently
registered thereunder or (B) the Securities to be sold or transferred may be sold or transferred pursuant to an exemption from
such registration; (2) any sale of the Securities made in reliance on Rule 144 promulgated under the 1933 Act (“Rule 144”)
may be made only in accordance with the terms of Rule 144 and further, if Rule 144 is not applicable, any resale of such Securities
under circumstances in which the seller, or the Person through whom the sale is made, may be deemed to be an underwriter, as that
term is used in the 1933 Act, may require compliance with some other exemption under the 1933 Act or the rules and regulations
of the SEC thereunder, (3) at the request of the Buyer, the Company shall, from time to time, within two (2) business days of
such request, at the sole cost and expense of the Company, either (i) deliver to its transfer agent and registrar for the Common
Stock (the “Transfer Agent”) a written letter instructing and authorizing the Transfer Agent to process transfers
of the Shares at such time as the Buyer has held the Securities for the minimum holding period permitted under Rule 144, subject
to the Buyer’s providing to the Transfer Agent certain customary representations contemporaneously with any requested transfer,
or (ii) at the Buyer’s option or if the Transfer Agent requires further confirmation of the availability of an exemption
from registration, furnish to the Buyer an opinion of the Company’s counsel in favor of the Buyer (and, at the request of
the Buyer, any agent of the Buyer, including but not limited to the Buyer’s broker or clearing firm) and the Transfer Agent,
reasonably satisfactory in form, scope and substance to the Buyer and the Transfer Agent, to the effect that a contemporaneously
requested transfer of shares does not require registration under the 1933 Act, pursuant to the 1933 Act, Rule 144 or other regulations
promulgated under the 1933 Act and (4) neither the Company nor any other Person is under any obligation to register the Securities
(other than pursuant to this Agreement) under the 1933 Act or to comply with the terms and conditions of any exemption thereunder.

 

b.
Restrictive Legend. The Buyer acknowledges and agrees that the Debentures, and, until such time as the Shares have been
registered under the 1933 Act as contemplated hereby and sold in accordance with an effective Registration Statement, certificates
and other instruments representing any of the Securities shall bear a restrictive legend in substantially the following form (and
a stop-transfer order may be placed against transfer of any such Securities):

 

THIS
SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE
UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY,
MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE
EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF
WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

c.
Piggy-Back Registration Rights. From and after the Signing Closing Date and until eighteen (18) months after the Signing
Closing Date, if the Company contemplates making an offering of Common Stock (or other equity securities convertible into or exchangeable
for Common Stock) registered for sale under the Securities Act or proposes to file a Registration Statement covering any of its
securities, the Company shall at each such time give prompt written notice to Investments and Buyer of its intention to do so
and of the registration rights granted under this Agreement. Upon the written request of Buyer made within thirty (30) days after
the receipt of any such notice (which request shall specify the Registrable Securities intended to be disposed of by Buyer and
the intended method of disposition thereof), the Company shall, at its sole cost and expense, use its best efforts to effect the
registration of all Registrable Securities which the Company has been so requested to register Buyer, to the extent requisite
to permit the disposition (in accordance with the intended methods of disposition) of the Registrable Securities by Buyer, by
inclusion of such Registrable Securities in the Registration Statement which covers the securities which the Company proposes
to register; provided, that if the Company is unable to register the full amount of Registrable Securities in an “at the
market offering” under SEC rules and regulations due to the high percentage of the Company’s Common Stock the Registrable
Securities represents (giving effect to all other securities being registered in the Registration Statement), then the Company
may reduce, on a pro rata basis, the amount of Registrable Securities subject to the Registration Statement to a lesser amount
which equals the maximum number of Registrable Securities that the Company is permitted to register in an “at the market
offering”; and provided, further, that if, at any time after giving written notice of its intention to register any Registrable
Securities and prior to the effective date of the Registration Statement filed in connection with such registration, the Company
shall determine for any reason either not to register or to delay registration of such Registrable Securities, the Company may,
at its election, give written notice of such determination to Investments and/or the Buyer and, thereupon, (i) in the case of
a determination not to register, the Company shall be relieved of its obligation to register any Registrable Securities in connection
with such registration (but not from its obligation to pay the expenses of registration in connection therewith), and (ii) in
the case of a determination to delay registering such Registrable Securities, shall be permitted to delay registering any Registrable
Securities, for the same period as the delay in registering such other securities. If Buyer shall have transferred all or part
of its Registrable Securities, then for purposes of this Section, the term “Buyer” shall reference Buyer and/or such
transferee(s).

 

    	9

    	 

    

 

d.
Securities Filings. The Company undertakes and agrees to make all necessary filings (including, without limitation, a Form
D) in connection with the sale of the Securities to the Buyer required under any United States laws and regulations applicable
to the Company (including without limitation state “blue sky” laws), or by any domestic securities exchange or trading
market, and to provide a copy thereof to the Buyer promptly after such filing.

 

e.
Reporting Status; Public Trading Market; DTC Eligibility. So long as the Buyer beneficially own any Securities, (i) the
Company shall timely file, prior to or on the date when due, all reports that would be required to be filed with the SEC pursuant
to Section 13 or 15(d) of the Exchange Act if the Company had securities registered under Section 12(b) or 12(g) of the Exchange
Act; (ii) the Company shall not be operated as, or report, to the SEC or any other Person, that the Company is a “shell
company” or indicate to the contrary to the SEC or any other Person; (iii) the Company shall take all other action under
its control necessary to ensure the availability of Rule 144 under the 1933 Act for the sale of Shares by the Buyer at the earliest
possible date; and (iv) the Company shall at all times while any Securities are outstanding maintain its engagement of an independent
registered public accounting firm. Except as otherwise set forth in Transaction Documents, the Company shall take all action under
its control necessary to obtain and to continue the listing and trading of its Common Stock (including, without limitation, all
Registrable Securities) on the OTC Markets, Inc. (“OTCM”) on the OTC Pink (“OTCP”), OTCQB (“OTCQB”),
or OTCQX (“OTCQX”), and will comply in all material respects with the Company’s reporting, filing and other
obligations under the by-laws or rules of the Financial Industry Regulatory Authority (“FINRA”). If, so long as the
Buyer beneficially own any of the Securities, the Company receives any written notice from the OTCM, FINRA, or the SEC with respect
to either any alleged deficiency in the Company’s compliance with applicable rules and regulations (including without limitation
any comments from the SEC on any of the Company’s documents filed (or the failure to have made any such filing) under the
1933 Act or the Exchange Act) (each, a “Regulatory Notice”), then the Company shall promptly, and in any event within
two (2) business days, provide copies of the Regulatory Notice to the Buyer, and shall promptly, and in any event within five
(5) business days of receipt of the Regulatory Notice (a “Regulatory Response”), respond in writing to the OTCM, FIRNA
and/or SEC (as the case may be), setting forth the Company’s explanation and/or response to the issues raised in the Regulatory
Notice, with a view towards maintaining and/or regaining full compliance with the applicable rules and regulations of the OTCM,
FIRNA and/or SEC and maintaining or regaining good standing of the Company with the OTCM, FINRA and/or SEC, as the case may be,
the intent being to ensure that the Company maintain its reporting company status with the SEC and that its Common Stock be and
remain available for trading on the OTCP, OTCQB, or OTCQX. Further, at all times while any Securities are outstanding, the Common
Stock shall be DWAC Operational, and the Common Stock shall not be subject to any DTC “chill” designation or similar
restriction on the clearing of the Common Stock through DTC.

 

    	10

    	 

    

 

f.
Use of Proceeds. The Company shall use the proceeds from the sale of the Debentures for working capital purposes only subject
to customary restrictions. Absent the prior written approval of a majority of the principal amount of the Debentures then outstanding,
the Company shall not use any portion of the proceeds of the sale of the Debentures to (i) repay any indebtedness or other obligation
of the Company incurred prior to the date of this Agreement outside the normal course of business, (ii) pay any dividends or redemption
amount on any of the Company’s equity or equity equivalents, (iii) pay any amounts, whether on account of debt obligations
of the Company or otherwise, except for compensation, to any officer, director or other related party of the Company or (iv) pay
deferred compensation or any compensation to any of the directors or officers of the Company in excess of the rate or amount paid
or accrued during the fiscal year ended September, 2016 (as base compensation and excluding any discretionary amounts), other
than modest increases consistent with prior practice that are approved by the Company’s Board of Directors.

 

g.
Available Shares. Commencing on the date of execution and delivery of this Agreement, the Company shall have and maintain
authorized and reserved for issuance, free from preemptive rights, that number of shares equal to Seven Hundred percent (700%)
of the number of shares of Common Stock (1) issuable based upon the conversion of the then-outstanding Debentures (including accrued
interest thereon) as may be required to satisfy the conversion rights of the Buyer pursuant to the terms and conditions of the
Debenture (for the avoidance of doubt, this shall be calculated based on the applicable conversion price that would result on
or after the date that is 180 days after the issuance date of the respective Debenture(s) regardless of the date of calculation)
(without giving effect to the 4.99% limitation on ownership as set forth in the Debentures), provided, however that for
purposes of the foregoing calculation, the full indebtedness under the Debentures shall be deemed immediately convertible and
(2) issuable to the Buyer on future Closing Dates, based upon the lowest closing bid price per share of the Common Stock on the
date before the most recent Closing Date (as reported by Bloomberg LP) (collectively in the aggregate the “Required Reserve
Amount”). The Company shall monitor its compliance with the foregoing requirements on an ongoing basis. If at any time the
Company does not have available an amount of authorized and non-issued Shares required to be reserved pursuant to this Section,
then the Company shall, without notice or demand by the Buyer, call within thirty (30) days of such occurrence and hold within
sixty (60) days of such occurrence a special meeting of shareholders, for the sole purpose of increasing the number of shares
authorized. Management of the Company shall recommend to shareholders to vote in favor of increasing the number of Common Stock
authorized at the meeting. Members of the Company’s management shall also vote all of their own shares in favor of increasing
the number of Common Stock authorized at the meeting. If the increase in authorized shares is approved by the stockholders at
the meeting, the Company shall implement the increase in authorized shares within one (1) business day following approval at such
meeting. Alternatively, to the extent permitted by applicable law, in lieu of calling and holding a meeting as described above,
the Company may, within thirty (30) days of the date when the Company does not have available an amount of authorized and non-issued
Shares required to be reserved as described above, procure the written consent of stockholders to increase the number of shares
authorized, and provide the stockholders with notice thereof as may be required under applicable law (including without limitation
Section 14(c) of the Exchange Act and Regulation 14C thereunder). Upon obtaining stockholder approval as aforesaid, the Company
shall cause the appropriate increase in its authorized shares of Common Stock within one (1) business day (or as soon thereafter
as permitted by applicable law). Company’s failure to comply with these provisions will be an Event of Default (as defined
in the Debentures).

 

h.
Reimbursement. If (i) Buyer and/or Investments becomes a party defendant in any capacity in any action or proceeding brought
by any stockholder of the Company, in connection with or as a result of the consummation of the transactions contemplated by the
Transaction Documents, or if the Buyer and/or Investments is impleaded in any such action, proceeding or investigation by any
Person, or (ii) the Buyer and/or Investments, other than by reason of its own gross negligence, willful misconduct or breach of
law (as adjudicated by a court of law having proper jurisdiction and such adjudication is not subject to appeal), becomes a party
defendant in any capacity in any action or proceeding brought by the SEC against or involving the Company or in connection with
or as a result of the consummation of the transactions contemplated by the Transaction Documents, or if the Buyer or Investments
is impleaded in any such action, proceeding or investigation by any Person, then in any such case, the Company shall promptly
reimburse the Buyer and/or Investments for its or their reasonable legal and other expenses (including the cost of any investigation
and preparation) incurred in connection therewith. The reimbursement obligations of the Company under this paragraph shall be
in addition to any liability which the Company may otherwise have, shall extend upon the same terms and conditions to any affiliates
of the Buyer and/or Investments who are actually named in such action, proceeding or investigation, and partners, directors, agents,
employees and controlling Persons (if any), as the case may be, of the Buyer, Investments and any such Affiliate, and shall be
binding upon and inure to the benefit of any successors, assigns, heirs and personal representatives of the Company, the Buyer,
Investments and any such Affiliate and any such Person. Except as otherwise set forth in the Transaction Documents, the Company
also agrees that neither any Buyer, Investments nor any such Affiliate, partners, directors, agents, employees or controlling
Persons shall have any liability to the Company or any Person asserting claims on behalf of or in right of the Company in connection
with or as a result of the consummation of the Transaction Documents.

 

    	11

    	 

    

 

i.
The Company shall provide the Transfer Agent and/or the Buyer, Investments or their respective brokerage and/or clearing firm
with all relevant legal opinions and other documentation requested by the Buyer or Investments in connection with the issuance
of the Conversion Shares or the Restricted Stock, or the sale thereof, to confirm the share issuance(s) such that the Conversion
Shares and/or Restricted Stock may be deposited with the applicable brokerage and/or clearing firm.

 

j.
No Payments to Affiliates or Related Parties. So long as any of the Debentures remain outstanding, if the Debentures are
in default, the Company shall not, absent the prior written consent of the holders of all Debentures then outstanding, make any
payments to any of the Company’s or the Subsidiaries’ respective affiliates or related parties, including without
limitation payments or prepayments of principal or interest accrued on any indebtedness or obligation in favor of affiliates or
related parties. Notwithstanding anything to the contrary contained herein, the provisions of this Section 4(j) shall not apply
to payments to the Subsidiaries, or other businesses in which affiliates have an interest, made in the ordinary course of business
and consistent with past practice as disclosed in the SEC Documents.

 

k.
Notice of Material Adverse Effect. The Company shall notify the Buyer (and any subsequent holder of the Debentures), as
soon as practicable and in no event later than three (3) business days of the Company’s knowledge of any Material Adverse
Effect on the Company. For purposes of the foregoing, “knowledge” means the earlier of the Company’s actual
knowledge or the Company’s constructive knowledge upon due inquiry.

 

l.
Public Disclosure. Except to the extent required by applicable law, absent the Buyer’s prior written consent, the
Company shall not reference the name of the Buyer in any press release, securities disclosure, business plan, marketing or funding
proposal.

 

m.
Nature of Transaction; Savings Clause. It is the parties’ express understanding and agreement that the transactions
contemplated by the Transaction Documents constitute an investment and not a loan. If nonetheless such transactions are deemed
to be a loan (as adjudicated by a court of law having proper jurisdiction and such adjudication is not subject to appeal), the
Company shall not be obligated or required to pay interest at a rate that could subject Buyer to either civil or criminal liability
as a result of such rate exceeding the maximum rate that the Buyer is permitted to charge under applicable law, and the Company’s
obligations under the Transaction Documents shall not be void or voidable on the basis of the Buyer’s lack of any license
or registration as a lender with any governmental authority. It is expressly understood and agreed by the parties that neither
the amounts payable pursuant to Section 12, any redemption premium, remedy upon an Event of Default (as defined in the Debentures)
or any Acceleration Amount (as defined in the Debentures), original issue discount nor any investment returns of the Buyer on
the sale of the Debentures or the sale of any Conversion Shares (whether unrealized or realized) shall be construed as interest.
If, by the terms of the Debentures, any other Transaction Document or any other instrument, Buyer is at any time required or obligated
to pay interest at a rate exceeding such maximum rate, interest payable under the Debenture and/or such other Transaction Documents
or other instrument shall be computed (or recomputed) at such maximum rate, and the portion of all prior interest payments (if
any) exceeding such maximum shall be applied to payment of the outstanding principal of the Debentures.

 

    	12

    	 

    

 

5.
TRANSFER AGENT INSTRUCTIONS.

 

a.
Transfer Agent Instruction Letter. On or before the Signing Closing Date, the Company shall irrevocably instruct its Transfer
Agent in writing using the letter substantially in the form of Exhibit B annexed hereto, with only such modifications as
the Buyer agrees to, executed by the Company, the Buyer and the Transfer Agent (the “Transfer Agent Instruction Letter”),
to (i) reserve that number of shares of Common Stock as is required under Section 4(g) hereof, and (ii) issue Common Stock from
time to time upon conversion of the Debentures in such amounts as specified from time to time by the Buyer to the Transfer Agent
in a Notice of Conversion, in such denominations to be specified by the Buyer in connection with each conversion of the Debentures.
The Transfer Agent shall not be restricted from issuing shares from only the allotment reserved hereunder for the Conversion Amount
(as defined in the Debentures), but instead may, to the extent necessary to satisfy the amount of shares issuable upon conversion,
issue shares above and beyond the amount reserved on account of the Conversion Amount, without any additional instructions or
authorization from the Company, and the Company shall not provide the Transfer Agent with any instructions or documentation contrary
to the foregoing. As of the date of this Agreement, the Transfer Agent is Pacific Stock Transfer Co.. The Company shall at all
times while any Debentures are outstanding engage a Transfer Agent which is a party to the Transfer Agent Instruction Letter.
If for any reason the Company’s Transfer Agent is not a signatory of the Transfer Agent Instruction Letter while any Debentures
or Restricted Stock are outstanding and held by the Buyer, then such Transfer Agent shall nonetheless be deemed bound by the Transfer
Agent Instruction Letter, and the Company shall neither (i) permit the Transfer Agent to disclaim, disregard or refuse to abide
by the Transfer Agent’s obligations, terms and agreements set forth in the Transfer Agent Instruction Letter, nor (ii) issue
any instructions to the Transfer Agent contrary to the obligations, terms and agreements set forth in the Transfer Agent Instruction
Letter . The Company shall not terminate the Transfer Agent or otherwise change Transfer Agents without at least fifteen (15)
days prior written notice to the Buyer and with the Buyer’s prior written consent to such change, which the Buyer may grant
or withhold in its sole discretion. The Company shall continuously monitor its compliance with the share reservation requirements
and, if and to the extent necessary to increase the number of reserved shares to remain and be at least the Required Reserve Amount
to account for any decrease in the Market Price of the Common Stock, the Company shall immediately (and in any event within one
(1) business day) notify the Transfer Agent in writing of the reservation of such additional shares, provided that in the
event that the number of shares reserved for conversion of the Debentures is less than the Required Reserve Amount, the Buyer
may also directly instruct the Transfer Agent to increase the reserved shares as necessary to satisfy the minimum reserved share
requirement, and the Transfer Agent shall act accordingly, provided, further, that the Company shall within one (1) business
day provide any written confirmation, assent or documentation thereof as the Transfer Agent may request to act upon a share increase
instruction delivered by the Buyer. The Company shall provide the Buyer with a copy of all written instructions to the Company’s
Transfer Agent with respect to the reservation of shares simultaneously with the issuance of such instructions to the Transfer
Agent. The Company covenants that no instruction other than such instructions referred to in this Section 5 and stop transfer
instructions to give effect to Section 4(a) hereof prior to registration and sale of the Conversion Shares under the 1933 Act
will be given by the Company to the Transfer Agent and that the Conversion Shares shall otherwise be freely transferable on the
books and records of the Company as and to the extent provided in this Agreement and applicable law. If the Buyer provides the
Company and/or the Transfer Agent with an opinion of counsel reasonably satisfactory to the Company that registration of a resale
by the Buyer of any of the Securities in accordance with clause (1)(B) of Section 4(a) of this Agreement is not required under
the 1933 Act, the Company shall (except as provided in clause (2) of Section 4(a) of this Agreement) permit the de-legending or
transfer of the Securities and, in the case of the Conversion Shares, instruct the Company’s Transfer Agent to issue one
or more certificates for Common Stock without legend in such name and in such denominations as specified by the Buyer.

 

b.
Conversion. (i) The Company shall permit the Buyer to exercise the right to convert the Debentures by faxing, emailing
or delivering overnight an executed and completed Notice of Conversion to the Company or the Transfer Agent. If so requested by
the Buyer or the Transfer Agent, the Company shall within one (1) business day respond with its endorsement so as to confirm the
outstanding principal amount of any Debenture submitted for conversion or shall reconcile any difference with the Buyer promptly
after receiving such Notice of Conversion.

 

(ii)
The term “Conversion Date” means, with respect to any conversion elected by the holder of the Debentures, the date
specified in the Notice of Conversion, provided the copy of the Notice of Conversion is given either via mail or facsimile to
or otherwise delivered to the Transfer Agent and/or the Company in accordance with the provisions hereof so that it is received
by the Transfer Agent and/or the Company on or before such specified date.

 

    	13

    	 

    

 

(iii)
The Company shall deliver (or will cause the Transfer Agent to deliver) the Conversion Shares issuable upon conversion as follows:
(1) if the Company is then DWAC Operational, via DWAC, (2) if the Common Stock is then eligible for the Depository Trust Company’s
Direct Registration System (“DRS”), if so requested by the Buyer, or (3) if the Company is not then DWAC Operational
or the Common Stock is not then eligible for DRS, in certificated form, to the Buyer at the address specified in the Notice of
Conversion (which may be the Buyer’s address for notices as contemplated by Section 10 hereof or a different address) via
express courier, in each case within two (2) business days (the “Delivery Date”) after (A) the business day on which
the Company or the Transfer Agent has received the Notice of Conversion (by facsimile, email or other delivery) or (B) the date
on which payment of interest and principal on the Debentures, which the Company has elected to pay by the issuance of Common Stock,
as contemplated by the Debentures, was due, as the case may be.

 

c.
Failure to Timely Issue Conversion Shares or De-Legended Shares. The Company’s failure to issue and deliver Conversion
Shares to the Buyer (either by DWAC, DRS or in certificated form, as required by Section 5(b)) on or before the Delivery Date
shall be considered an Event of Default, which shall entitle the Buyer to certain remedies set forth in the Debentures and provided
by applicable law. Similarly, the Company’s failure to issue and deliver Common Stock in unrestricted form without
a restrictive legend when required under the Transaction Documents shall entitle the Buyer to damages for the diminution in value
(if any) of the relevant shares between the date delivery was due versus the date ultimately delivered in unrestricted form. The
Company acknowledges that its failure to timely honor a Notice of Conversion (or the occurrence of any other Event of Default)
shall cause definable financial hardship on the Buyer(s) and that the remedies set forth herein and in the Debentures are reasonable
and appropriate.

 

d.
Duties of Company; Authorization. The Company shall inform the Transfer Agent of the reservation of shares contemplated
by Section 4(g) and this Section 5, and shall keep current in its payment obligations to the Transfer Agent such that the Transfer
Agent will continue to process share transfers and the initial issuance of shares of Common Stock upon the conversion of Debentures.
The Company hereby authorizes and agrees to authorize the Transfer Agent to correspond and otherwise communicate with the Buyer
or their representatives in connection with the foregoing and other matters related to the Common Stock. Further, the Company
hereby authorizes the Buyer or its representative to provide instructions to the Transfer Agent that are consistent with the foregoing
and instructs the Transfer Agent to honor any such instructions. Should the Company fail for any reason to keep current in its
payment obligations to the Transfer Agent, the Buyer and/or Investments may pay such amounts as are necessary to compensate the
Transfer Agent for performing its duties with respect to share reservation, issuance of Conversion Shares and/or de-legending
certificates representing Restricted Stock, and all amounts so paid shall be promptly reimbursed by the Company. If not so reimbursed
within thirty (30) days, such amounts shall, at the option of the Buyer and without prior notice to or consent of the Company,
be added to the principal amount due under the Debenture(s) held by the Buyer, whereupon interest will begin to accrue on such
amounts at the rate specified in the Debentures.

 

e.
Effect of Bankruptcy. The Buyer shall be entitled to exercise its conversion privilege with respect to the Debentures notwithstanding
the commencement of any case under 11 U.S.C. §101 et seq. (the “Bankruptcy Code”). In the event the Company
is a debtor under the Bankruptcy Code, the Company hereby waives, to the fullest extent permitted, any rights to relief it may
have under 11 U.S.C. §362 in respect of the Buyer’s conversion privilege. The Company hereby waives, to the fullest
extent permitted, any rights to relief it may have under 11 U.S.C. §362 in respect of the conversion of the Debentures. The
Company agrees, without cost or expense to the Buyer, to take or to consent to any and all action necessary to effectuate relief
under 11 U.S.C. §362.

 

6.
CLOSINGS. 

 

a.
Signing Closing. Promptly upon the execution and delivery of this Agreement, the Signing Debenture, Warrant, and all conditions
in Sections 7 and 8 herein are met (the “Signing Closing Date”), (A) the Company shall deliver to the Buyer the following:
(i) the Signing Debenture and Warrant; (ii) the Transfer Agent Instruction Letter; (iii) duly executed counterparts of the Transaction
Documents; and (iv) an officer’s certificate of the Company confirming the accuracy of the Company’s representations
and warranties contained herein, and (B) the Buyer shall deliver to the Company the following: (i) the Signing Purchase Price
and (ii) duly executed counterparts of the Transaction Documents (as applicable). The Company shall immediately pay the fees due
under Section 12 of this Agreement upon receipt of the Signing Purchase Price if Buyer does not withhold such amounts from the
Signing Purchase Price pursuant to Section 12.

 

    	14

    	 

    

 

b.
Second Closing. At any time after sixty (60) days following the Signing Closing Date, subject to the mutual agreement of
the Buyer and the Company, for the “Second Closing Date” and subject to satisfaction of the conditions set forth in
Sections 7 and 8, (A) the Company shall deliver to the Buyer the following: (i) the Second Debenture; (ii) an amendment to the
Transfer Agent Instruction Letter instructing the Transfer Agent to reserve that number of shares of Common Stock as is required
under Section 4(g) hereof, if necessary; and (iii) an officer’s certificate of the Company confirming, as of the Second
Closing Date, the accuracy of the Company’s representations and warranties contained herein and updating Schedules 3(b),
3(c) and 3(k) as of the Second Closing Date, and (B) the Buyer shall deliver to the Company the Second Purchase Price.

 

c.
[Intentionally Omitted].

 

d.
Location and Time of Closings. Each Closing shall be deemed to occur on the related Closing Date at the office of the Buyer’s
counsel and shall take place no later than 5:00 P.M., east coast time, on such day or such other time as is mutually agreed upon
by the Company and the Buyer.

 

7.
CONDITIONS TO THE COMPANY’S OBLIGATION TO SELL.

 

The
Company’s obligation to sell the Debentures to the Buyer pursuant to this Agreement on each Closing Date is conditioned
upon:

 

a.
Purchase Price. Delivery to the Company of good funds as payment in full of the respective Purchase Price for the Debentures
at each Closing in accordance with this Agreement;

 

b.
Representations and Warranties; Covenants. The accuracy on the Closing Date of the representations and warranties of the
Buyer contained in this Agreement, each as if made on such date, and the performance by the Buyer on or before such date of all
covenants and agreements of the Buyer required to be performed on or before such date; and

 

c.
Laws and Regulations; Consents and Approvals. There shall not be in effect any law, rule or regulation prohibiting or restricting
the transactions contemplated hereby, or requiring any consent or approval which shall not have been obtained.

 

8.
CONDITIONS TO THE BUYER’S OBLIGATION TO PURCHASE.

 

The
Buyer’s obligation to purchase the Debentures at each Closing is conditioned upon:

 

a.
Transaction Documents. The execution and delivery of this Agreement by the Company;

 

b.
Debenture(s). Delivery by the Company to the Buyer of the Debentures to be purchased in accordance with this Agreement;

 

c.
Section 4(2) Exemption. The Debentures and the Conversion Shares shall be exempt from registration under the Securities
Act of 1933 (as amended), pursuant to Section 4(2) thereof;

 

d.
DWAC Status. The Common Stock shall be DWAC Operational;

 

e.
Representations and Warranties; Covenants. The accuracy in all material respects on the Closing Date of the representations
and warranties of the Company contained in this Agreement, each as if made on such date, and the performance by the Company on
or before such date of all covenants and agreements of the Company required to be performed on or before such date;

 

f.
Good-faith Opinion. It should be Buyer’s reasonable belief that (i) no Event of Default under the terms of any outstanding
indebtedness of the Company shall have occurred or would likely occur with the passage of time and (ii) no material adverse change
in the financial condition or business operations of the Company shall have occurred;

 

    	15

    	 

    

 

g.
Legal Proceedings. There shall be no litigation, criminal or civil, regulatory impairment or other legal and/or administrative
proceedings challenging or seeking to limit the Company’s ability to issue the Securities or the Common Stock;

 

h.
[Reserved];

 

i.
Corporate Resolutions. Delivery by the Company to the Buyer a copy of resolutions of the Company’s board of directors,
approving and authorizing the execution, delivery and performance of the Transaction Documents and the transactions contemplated
thereby in the form attached hereto as Exhibit C (the “Irrevocable Resolutions”);

 

j.
Officer’s Certificate. Delivery by the Company to the Buyer of a certificate of the Chief Executive Officer of the
Company in the form attached hereto as Exhibit D;

 

k.
Search Results. Delivery by the Company to the Buyer of copies of UCC search reports, issued by the Secretary of State
of the state of incorporation of the Company and each Subsidiary, dated such a date as is reasonably acceptable to Buyer, listing
all effective financing statements which name the Company or Subsidiary (as applicable), under its present name and any previous
names, as debtor, together with copies of such financing statements;

 

l.
Certificate of Good Standing. Delivery by the Company to the Buyer of a copy of a certificate of good standing with respect
to the Company, issued by the Secretary of State of the state of incorporation of the Company, dated such a date as is reasonably
acceptable to Buyer, evidencing the good standing thereof;

 

m.
Laws and Regulations; Consents and Approvals. There shall not be in effect any law, rule or regulation prohibiting or restricting
the transactions contemplated hereby, or requiring any consent or approval which shall not have been obtained; and

 

n.
Adverse Changes. From and after the date hereof to and including each Closing Date, (i) the trading of the Common Stock
shall not have been suspended by the SEC, FINRA, or any other governmental or self-regulatory organization, and trading in securities
generally on OTCM shall not have been suspended or limited, nor shall minimum prices been established for securities traded on
the OTCM; (ii) there shall not have occurred any outbreak or escalation of hostilities involving the United States or any material
adverse change in any financial market that in either case in the reasonable judgment of the Buyer makes it impracticable or inadvisable
to purchase the Debentures.

 

9.
GOVERNING LAW; MISCELLANEOUS. 

 

a.
MANDATORY FORUM SELECTION. Any dispute arising under, relating to, or in connection
with the Agreement or related to any matter which is the subject of or incidental to the Agreement (whether or not such claim
is based upon breach of contract or tort) shall be subject to the exclusive jurisdiction and venue of the state and/or federal
courts located in MIAMI-DADE County, FLORIDA. This provision is intended to be a “mandatory” forum selection clause
and governed by and interpreted consistentLY with Nevada law.

 

b.
Governing Law. Except in the case of the Mandatory Forum Selection clause above, this Agreement shall be delivered and
accepted in and shall be deemed to be contracts made under and governed by the internal laws of the State of Nevada, and for all
purposes shall be construed in accordance with the laws of the State of Nevada, without giving effect to the choice of law provisions.
To the extent determined by the applicable court described above, the Company shall reimburse the Buyer for any reasonable legal
fees and disbursements incurred by the Buyer in enforcement of or protection of any of its rights under any of the Transaction
Documents.

 

    	16

    	 

    

 

c.
Waivers. Failure of any party to exercise any right or remedy under this Agreement or otherwise, or delay by a party in
exercising such right or remedy, shall not operate as a waiver thereof.

 

d.
Successors and Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and assigns of
each of the parties hereto.

 

e.
Construction. All pronouns and any variations thereof refer to the masculine, feminine or neuter, singular or plural, as
the context may require.

 

f.
Facsimiles; E-mails. A facsimile or email transmission of this signed Agreement or a Notice of Conversion under the Debentures
shall be legal and binding on all parties hereto. Such electronic signatures shall be the equivalent of original signatures.

 

g.
Counterparts. This Agreement may be signed in one or more counterparts, each of which shall be deemed an original.

 

h.
Headings. The headings of this Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Agreement.

 

i.
Enforceability. If any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, such invalidity
or unenforceability shall not affect the validity or enforceability of the remainder of this Agreement or the validity or enforceability
of this Agreement in any other jurisdiction.

 

j.
Amendment. This Agreement may be amended only by the written consent of a majority in interest of the holders of the Debentures
and an instrument in writing signed by the Company.

 

k.
Entire Agreement. This Agreement, together with the other Transaction Documents, supersedes all prior agreements and understandings
among the parties hereto with respect to the subject matter hereof.

 

l.
No Strict Construction. This Agreement shall be construed as if both Parties had equal say in its drafting, and thus shall
not be construed against the drafter.

 

m.
Further Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things,
and shall execute and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably
request in order to carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions
contemplated hereby.

 

10.
NOTICES.

 

Any
notice required or permitted hereunder shall be given in writing (unless otherwise specified herein) and shall be deemed effectively
given on the earliest of:

 

a.
the date delivered, if delivered by personal delivery as against written receipt therefor or by confirmed facsimile or email transmission,

 

b.
the third (3rd) business day after deposit, postage prepaid, in the United States Postal Service by registered or certified
mail, or

 

    	17

    	 

    

 

c.
the first (1st) business day after deposit with a recognized courier service (e.g. FedEx, UPS, DHL, US Postal Service)
for delivery by next-day express courier, with delivery costs and fees prepaid,

 

in
each case, addressed to each of the other parties thereunto entitled at the following addresses (or at such other addresses as
such party may designate by ten (10) days’ advance written notice similarly given to each of the other parties hereto):

 

	COMPANY:
    	Cipherloc
        Corporation

        825
        Main Street, Suite 100

        Buda,
        TX 78610

        Attention:
        Michael De La Garza, Chief Executive Officer

        Email:
        mdlg@cipherloc.net

	 	 
	 

         
	With
        copies to (which shall not constitute notice):

         

        _______________________________

        _______________________________

        _______________________________

        Attention:
        ______________________

        Email:
        _________________________

	 	 
	BUYER:	Peak
        One Opportunity Fund, L.P.

        333
        South Hibiscus Drive

        Miami
        Beach, FL 33139

        Attention:
        Jason Goldstein

        Email:
        jgoldstein@peakoneinvestments.com

	 	 
	 	With
    copies to (which shall not constitute notice):
	 	 
	 	Legal
        & Compliance, LLC

        330
        Clematis Street, Suite 217

        West
        Palm Beach, FL 33401

        Attention:
        Chad Friend, Esq., LL.M.

        Email:
        CFriend@LegalandCompliance.com

 

11.
SURVIVAL OF REPRESENTATIONS AND WARRANTIES. The Company’s representations and warranties herein shall survive for
so long as any Debentures are outstanding, and shall inure to the benefit of the Buyer, its successors and assigns.

 

12.
FEES; EXPENSES.

 

a.
Commitment Fee. The Company shall pay to Investments a non-accountable fee (the “Commitment Fee”) of (i) Five
Thousand and 00/100 Dollars ($5,000.00) on the Signing Closing Date (with respect to the Signing Debenture), as well as Two Thousand
Five Hundred and 00/100 Dollars ($2,500.00) on the Second Closing Date (with respect to the Second Debenture), for Investments’
expenses and analysis performed in connection with the analysis of the Company and the propriety of the Buyer’s making the
contemplated investment. The Commitment Fee shall be paid on the respective closing dates if Buyer does not withhold such amounts
from the respective purchase price pursuant to Section 12(c).

 

    	18

    	 

    

 

b.
Legal Fees. The Company shall pay the legal fees of the Buyer’s counsel (the “Legal Fees”) in the amount
of Three Thousand Five Hundred and 00/100 Dollars ($3,500.00) on the Signing Closing Date (with respect to the Signing Debenture),
as well as Two Thousand Five Hundred and 00/100 Dollars ($2,500.00) on the Second Closing Date (with respect to the Second Debenture).
The foregoing legal fees shall be paid on the respective closing dates if Buyer does not withhold such amounts from the respective
purchase price pursuant to Section 12(c). The Company further agrees to pay in full the reasonable legal fees of the Buyer’s
counsel incurred after the Signing Closing Date incurred in connection with the Transaction Documents (including addressing any
purported breach(es) or default(s) by the Company, enforcement of the Company’s obligations or the exercise of the Buyer’s
remedies thereunder).

 

c. Disbursements. In
furtherance of the foregoing, the Company hereby authorizes the Buyer to deduct the cash portion of the Commitment Fee and
the Legal Fees from the Signing Purchase Price and transmit same to the respective payee.

 

[Signature
Page Follows]

 

    	19

    	 

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed by the Buyer and the Company as of the date first set forth above.

 

	 	COMPANY:
	 	 	 
	 	CIPHERLOC CORPORATION
	 	 	 
	 	By:
    	/s/
    Michael De La Garza
	 	Name:	Michael
    De La Garza
	 	Title:	Chief
    Executive Officer
	 	 	 
	 	By:

        
	Peak
One Investments, LLC, General Partner

	 	 	 
	 	By:	/s/
    Jason Goldstein
	 	Name:	Jason
    Goldstein
	 	Title:	Managing
    Member

 

[Signature
Page to Securities Purchase Agreement]

 

    	 

    	 

    

 

SCHEDULE
3(b)

 

COMPANY
ORGANIZATION CHART

 

	Subsidiary
        / Affiliate 

        Name
        and Relationship
	 	Jurisdiction
    of Incorporation	 	Percentage
    of Ownership
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 
	 	 	 	 	 

 

    	 

    	 

    

 

SCHEDULE
3(c)

 

COMPANY
CAPITALIZATION TABLE

COMMON
STOCK AND COMMON STOCK EQUIVALENTS 

ISSUED,
OUTSTANDING AND RESERVED

 

	DESCRIPTION	 	AMOUNT
	Authorized
    Common Stock	 	 
	Authorized
    Capital Stock	 	 
	Authorized
    Common Stock	 	 
	Issued
    Common Stock	 	 
	Outstanding
    Common Stock	 	 
	Treasury
    Stock	 	 
	Authorized,
    but unissued	 	 
	 	 	 
	Authorized
    Preferred Stock	 	 
	Issued
    Preferred Stock	 	 
	 	 	 
	Reserved
    for Equity Incentive Plans	 	 
	Reserved
    for Convertible Debt	 	 
	Reserved
    for Options and Warrants	 	 
	Reserved
    for Other Purposes	 	 
	 	 	 
	TOTAL
    COMMON STOCK AND COMMON STOCK EQUIVALENTS OUTSTANDING	 	 

 

    	 

    	 

    

 

 EXHIBITS

	Exhibit
    A	 	FORM
    OF DEBENTURE 
	 	 	 
	Exhibit
    B	 	FORM
    OF TRANSFER AGENT INSTRUCTION LETTER
	 	 	 
	Exhibit
    C	 	FORM
    OF RESOLUTIONS OF THE BOARD OF DIRECTORS
	 	 	 
	Exhibit
    D	 	FORM
    OF OFFICER’S CERTIFICATE

 

    	 

    	 

    

 

EXHIBIT
A

FORM
OF DEBENTURE

 

(see
attached)

 

    	 

    	 

    

 

EXHIBIT
B

 

CIPHERLOC
CORPORATION

 

IRREVOCABLE
TRANSFER AGENT INSTRUCTION LETTER

 

(see
attached)

 

    	 

    	 

    

 

EXHIBIT
C

 

IRREVOCABLE
CORPORATE RESOLUTIONS OF THE

BOARD
OF DIRECTORS OF

CIPHERLOC
CORPORATION

 

(see
attached)

 

    	 

    	 

    

 

EXHIBIT
D

 

OFFICER’S
CERTIFICATE

 

(see
attached)

 

    	 

    	 

    

 

EXHIBIT
I

 

ARTICLES
OF INCORPORATION

 

(see
attached)

 

    	 

    	 

    

 

EXHIBIT
II

 

BYLAWS

 

(see
attached)

 

    	 

    	 

    

 

EXHIBIT
III

 

RESOLUTIONS
OF THE BOARD OF DIRECTORS

 

(see
attached)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00278-of-00352.parquet"}]]